EP1463524A4 - Verfahren oder therapie für nicht-hodgkin-lymphom - Google Patents
Verfahren oder therapie für nicht-hodgkin-lymphomInfo
- Publication number
- EP1463524A4 EP1463524A4 EP02797231A EP02797231A EP1463524A4 EP 1463524 A4 EP1463524 A4 EP 1463524A4 EP 02797231 A EP02797231 A EP 02797231A EP 02797231 A EP02797231 A EP 02797231A EP 1463524 A4 EP1463524 A4 EP 1463524A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- hodgkin
- lymphoma
- therapy
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US293664 | 1999-04-16 | ||
US1796801A | 2001-12-07 | 2001-12-07 | |
US17968 | 2001-12-07 | ||
US10/293,664 US20030185796A1 (en) | 2000-03-24 | 2002-11-12 | Methods of therapy for non-hodgkin's lymphoma |
PCT/US2002/039253 WO2003049694A2 (en) | 2001-12-07 | 2002-12-06 | Methods of therapy for non-hodgkin's lymphoma |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1463524A2 EP1463524A2 (de) | 2004-10-06 |
EP1463524A4 true EP1463524A4 (de) | 2005-02-09 |
Family
ID=26690566
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02797231A Withdrawn EP1463524A4 (de) | 2001-12-07 | 2002-12-06 | Verfahren oder therapie für nicht-hodgkin-lymphom |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1463524A4 (de) |
JP (1) | JP2005538034A (de) |
AU (1) | AU2002362098A1 (de) |
CA (1) | CA2469045A1 (de) |
WO (1) | WO2003049694A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60332957D1 (de) | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
KR20060027801A (ko) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | B 세포 장애에 대한 조합 요법 |
US8147832B2 (en) * | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
WO2005062929A2 (en) * | 2003-12-22 | 2005-07-14 | Chiron Coporation | Use of fc receptor polymorphisms as diagnostics for treatment strategies for immune-response disorders |
PL1758610T3 (pl) | 2004-05-20 | 2012-11-30 | Zymogenetics Inc | Sposoby leczenia raka z zastosowaniem IL-21 i terapii przeciwciałem monoklonalnym |
US20060051345A1 (en) | 2004-06-04 | 2006-03-09 | Genentech, Inc. | Method for treating multiple sclerosis |
KR20070108402A (ko) * | 2005-02-15 | 2007-11-09 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | 화학요법제와 il-2 및 선택적으로 항-cd20 항체의조합물을 사용하여 임파종을 치료하는 방법 |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
CA2629306A1 (en) | 2005-11-23 | 2007-05-31 | Genentech, Inc. | Methods and compositions related to b cell assays |
SI3597659T1 (sl) | 2007-07-09 | 2023-04-28 | Genentech, Inc. | Preprečevanje redukcije disulfidne vezi med rekombinantno proizvodnjo polipeptidov |
EP2200631A1 (de) | 2007-10-16 | 2010-06-30 | Zymogenetics, Inc. | Kombination aus blys-hemmung und anti-cd20-wirkstoffen zur behandlung von autoimmunerkrankungen |
US7914785B2 (en) | 2008-01-02 | 2011-03-29 | Bergen Teknologieverforing As | B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome |
EP2077281A1 (de) | 2008-01-02 | 2009-07-08 | Bergen Teknologioverforing AS | Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom |
ATE548052T1 (de) * | 2008-01-17 | 2012-03-15 | Philogen Spa | Kombination aus einem anti-edb-fibronectin- antikörper-il-2-fusionsprotein und einem b-zellen bindenden molekül, b-zellen-vorläufern und/oder deren krebserregendem gegenspieler |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
HUE048980T2 (hu) | 2009-08-11 | 2020-08-28 | Hoffmann La Roche | Fehérjék elõállítása glutaminmentes sejttenyésztõ táptalajban |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
DK3313879T3 (da) | 2015-06-24 | 2022-03-14 | Hoffmann La Roche | Anti-transferrinreceptor-antistoffer med tilpasset affinitet |
CN114014936A (zh) | 2015-10-02 | 2022-02-08 | 豪夫迈·罗氏有限公司 | 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法 |
CN115369086B (zh) * | 2022-02-22 | 2023-05-12 | 北京景达生物科技有限公司 | 一种nk细胞扩大培养的培养方案 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001072333A1 (en) * | 2000-03-24 | 2001-10-04 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2 |
-
2002
- 2002-12-06 AU AU2002362098A patent/AU2002362098A1/en not_active Abandoned
- 2002-12-06 EP EP02797231A patent/EP1463524A4/de not_active Withdrawn
- 2002-12-06 CA CA002469045A patent/CA2469045A1/en not_active Abandoned
- 2002-12-06 JP JP2003550745A patent/JP2005538034A/ja not_active Withdrawn
- 2002-12-06 WO PCT/US2002/039253 patent/WO2003049694A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001072333A1 (en) * | 2000-03-24 | 2001-10-04 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination_of an antibody to cd20 and interleuking-2 |
Non-Patent Citations (11)
Title |
---|
BLOOD, vol. 98, no. 11 Part 2, 16 November 2001 (2001-11-16), 43RD ANNUAL MEETING OF THE AMERICAN SOCIETY OF HEMATOLOGY, PART 2; ORLANDO, FLORIDA, USA; DECEMBER 07-11, 2001, pages 250b, ISSN: 0006-4971 * |
CANCER IMMUNOLOGY, IMMUNOTHERAPY : CII. AUG 1998, vol. 46, no. 6, August 1998 (1998-08-01), pages 318 - 326, ISSN: 0340-7004 * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 16 November 2001 (2001-11-16), THUMMALA ANURADHA R ET AL: "A Phase I/II study of Rituxan and interleukin 2 (IL-2) in patients with low grade or mantle cell non Hodgkins lymphoma (NHL): Preliminary results", XP001204186, Database accession no. PREV200200152443 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; June 2002 (2002-06-01), ATKINS M B: "Interleukin-2: Clinical applications", XP009041149, Database accession no. EMB-2002208050 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; August 1998 (1998-08-01), MEROPOL N J ET AL: "Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing.", XP001204063, Database accession no. NLM9756416 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2000 (2000-07-01), FEHNIGER T A ET AL: "Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.", XP001204064, Database accession no. NLM10880055 * |
JANAKIRAMAN N ET AL: "RITUXIMAB: CORRELATION BETWEEN EFFECTOR CELLS AND CLINICAL ACTIVITYIN NHL", BLOOD, W.B. SAUNDERS, PHILADELPHIA, VA, US, vol. 92, no. 10,SUP01 PT01, 15 November 1998 (1998-11-15), pages 337A, XP001009992, ISSN: 0006-4971 * |
LEGET G A ET AL: "USE OF RITUXIMAB, THE NEW FDA-APPROVED ANTIBODY", CURRENT OPINION IN ONCOLOGY, CURRENT SCIENCE LTD, US, vol. 10, no. 6, November 1998 (1998-11-01), pages 548 - 551, XP000952702, ISSN: 1040-8746 * |
SEMINARS IN ONCOLOGY 2002 UNITED STATES, vol. 29, no. 3 SUPPL. 7, 2002, pages 12 - 17, ISSN: 0093-7754 * |
THE JOURNAL OF CLINICAL INVESTIGATION. JUL 2000, vol. 106, no. 1, July 2000 (2000-07-01), pages 117 - 124, ISSN: 0021-9738 * |
YIRINEC B ET AL: "Preliminary report on biological effects of rituxan (R) and interleukin-2 (IL-2) in patients with low-grade or mantle cell non-Hodgkins lymphoma (NHL)", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 94, no. 10 suppl 1 part 2, 15 November 1999 (1999-11-15), pages 270b, XP002170813, ISSN: 0006-4971 * |
Also Published As
Publication number | Publication date |
---|---|
EP1463524A2 (de) | 2004-10-06 |
WO2003049694A2 (en) | 2003-06-19 |
AU2002362098A1 (en) | 2003-06-23 |
AU2002362098A8 (en) | 2003-06-23 |
CA2469045A1 (en) | 2003-06-19 |
WO2003049694A3 (en) | 2003-11-06 |
JP2005538034A (ja) | 2005-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1463524A4 (de) | Verfahren oder therapie für nicht-hodgkin-lymphom | |
GB2393202B (en) | Methods of well treatment | |
AU2002348135A1 (en) | Methods for the treatment of addiction | |
GB0129976D0 (en) | Treatment method | |
EP1463495A4 (de) | Mittel und verfahren zur krebsbehandlung | |
GB0118383D0 (en) | Therapeutic methods | |
HUP0302739A3 (en) | Method for the treatment of tobacco | |
GB0124124D0 (en) | Methods of treatment | |
EP1389105A4 (de) | Behandlungsverfahren | |
GB0120147D0 (en) | Treatment method | |
GB0210741D0 (en) | Methods of therapy | |
GB0112216D0 (en) | Method of treatment | |
GB0130763D0 (en) | Treatment methods | |
GB0118892D0 (en) | Method of treatment | |
AU2004281077A1 (en) | Methods and agents for the treatment of cancer | |
GB0221712D0 (en) | Methods of treatment | |
EP1450849A4 (de) | Verfahren zur behandlung von endometreose | |
GB0126253D0 (en) | Treatment method | |
AU2002232563A1 (en) | Compounds for therapy and diagnosis and methods for using same | |
AU2002367463A8 (en) | Novel p53bp2 compounds for therapy and diagnosis and methods for using same | |
AUPR950401A0 (en) | Methods for treatment | |
AU2003905726A0 (en) | Methods and agents for the treatment of cancer | |
GB0116029D0 (en) | Method of treatment | |
GB0126094D0 (en) | Method of treatment | |
GB0125105D0 (en) | Method of treatment |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040706 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041228 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 35/00 B Ipc: 7A 61K 38/20 B Ipc: 7A 61K 39/395 A |
|
17Q | First examination report despatched |
Effective date: 20050331 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1070270 Country of ref document: HK |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC. |
|
17Q | First examination report despatched |
Effective date: 20050331 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20100701 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1070270 Country of ref document: HK |